pSivida Corp. (NASDAQ:PSDV) Files An 8-K Other Events

pSivida Corp. (NASDAQ:PSDV) Files An 8-K Other Events

Story continues below

Item8.01. Other Events.

On December19, 2016, pSivida Corp. (the Company) distributed a
letter to the Companys investors email distribution list
discussing its recent changes to the Companys leadership team and
its future plans for research, development and commercialization.
A copy of the letter is attached as Exhibit 99.1 hereto.


Various statements made in the letter are forward-looking, and
are inherently subject to risks, uncertainties and potentially
inaccurate assumptions. All statements that address activities,
events or developments that the Company intends, expects or
believes may occur in the future are forward-looking statements.
Some of the factors that could cause actual results to differ
materially from the anticipated results or other expectations
expressed, anticipated or implied in the Companys forward-looking
statements include uncertainties with respect to: the Companys
ability to obtain needed capital; the Companys ability to achieve
profitable operations; potential declines in Retisert royalties;
fluctuations in the Companys operating results; further
impairment of the Companys intangible assets; the Companys
ability to obtain marketing approvals for and successfully
commercialize Durasert three-year uveitis for posterior segment
uveitis; performance by CROs, vendors and investigators; timing
of filing marketing approval applications for Durasert three-year
uveitis; acceptability of data to be filed in support of Durasert
three-year uveitis marketing applications; maintenance of
European orphan designation for Durasert three-year uveitis;
potential off-label sales of ILUVIEN for posterior segment
uveitis; successful commercialization of, and receipt of revenues
from, ILUVIEN for DME; Alimeras ability to continue as a going
concern; the effect of pricing and reimbursement decisions on
sales of ILUVIEN for DME; consequences of fluocinolone acetonide
side effects; outcome of dispute with Alimera on
commercialization expenses; any exercise by Pfizer of its option
with respect to the latanoprost product; the Companys ability to
develop Tethadur to successfully deliver large biologic molecules
and develop products using it; efficacy and future development of
severe OA implant by the Company; the Companys ability to
successfully develop product candidates, initiate and complete
clinical trials and receive regulatory approvals; the Companys
ability to market and sell products; the success of current and
future license agreements; termination or breach of current
license agreements; effects of competition and other developments
affecting sales of products; market acceptance of products;
effects of guidelines, recommendations and studies; protection of
intellectual property and avoiding intellectual property
infringement; retention of key personnel; product liability;
industry consolidation; compliance with environmental laws;
manufacturing risks; risks and costs of international business
operations; effects of potential U.K. exit from the EU;
legislative or regulatory changes; volatility of stock price;
possible dilution; absence of dividends; and other factors
described in the Companys filings with the SEC. You should read
and interpret any forward-looking statements in light of these
risks. Should known or unknown risks materialize, or should
underlying assumptions prove inaccurate, actual results could
differ materially from past results and those anticipated,
estimated or projected in the forward-looking statements. You
should bear this in mind as you consider any forward-looking
statements. The Companys forward-looking statements speak only as
of the dates on which they are made. The Company does not
undertake any obligation to publicly update or revise its
forward-looking statements even if experience or future changes
makes it clear that any projected results expressed or implied in
such statements will not be realized.

Item9.01. Financial Statements and Exhibits.


Exhibit No.


99.1 Letter to Stockholders dated December 19, 2016

About pSivida Corp. (NASDAQ:PSDV)

An ad to help with our costs